nolatrexed
Small moleculeexperimental
Nolatrexed is a thymidylate synthase inhibitor. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00012324)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Thymidylate synthaseANTAGONIST
Thymidylate synthase antagonist
- Thymidylate synthaseINHIBITOR
TYMS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2nc(N)[nH]c(=O)c2c1Sc1ccncc1- Mol. weight
- 284.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNolatrexed ↗
- ChEMBLCHEMBL320775 ↗
Also known as
- 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride
- ag337
- ag 337
- ag-337
- nolatrexed
- nolatrexed
- nolatrexed
- nolatrexed
- nolatrexed dihydrochloride
- nolatrexed dihydrochloride
- nolatrexed dihydrochloride
- thymitaq
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00012324 | Phase 3 | Sep 1, 2000 | Eximias Pharmaceutical |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eximias Pharmaceutical | For profit | 1 | 1 | 1 | 2000 |
1 organizations
Page 1 / 1